Madhan Kolappan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Madhan Kolappan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alan J. Thompson
Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom
1 shared publication - Alastair Compston
Cambridge, UK
1 shared publication - Andrew W. Michell
From the Department of Clinical Neurophysiology, Addenbrooke's Hospital, Cambridge, United Kingdom
1 shared publication - Charles Crawley
NMR Research Unit, Dept. of Neuroinflammation, UCL Institute of Neurology, London, UK
1 shared publication - Claudia Angewla Michela Gandini Wheeler-Kingshott
Department of Brain and Behavioral Sciences, University of Pavia
1 shared publication - Daniel J. Tozer
UCL Institute of Neurology, London, UK
1 shared publication
Latest Publications
- Open Access
- 2 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 62
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes - the "sentinel lesion approach".
- 2 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 62
Open AccessThe mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes - the "sentinel lesion approach".